Nov. 27, 2025	Teijin Pharma to Receive $5 Million Milestone Payment from Bioprojet for Initiating Phase 1 Clinical Trial of Narcolepsy Drug Candidate
Nov. 06, 2025	Teijin Pharma Launches YORVIPATH®, a First of its Kind Treatment in Japan for the Rare Disease Hypoparathyroidism
Oct. 23, 2025	Teijin Pharma Signs Licensing Agreement Giving UK Biotech Firm Exclusive Global Development and Commercialization Rights to Rheumatoid Arthritis Drug Candidate
Aug. 25, 2025	Teijin Pharma Receives Manufacturing and Marketing Approval in Japan for YORVIPATH® as the Treatment for Hypoparathyroidism
Jun. 24, 2025	Teijin Pharma Receives Approval for Additional Indication for XEOMIN® in Japan
Jun. 03, 2025	Navepegritide Designated as an Orphan Drug by Japan’s Ministry of Health, Labor and Welfare

Page Top